{"id":1460,"date":"2018-07-03T16:14:04","date_gmt":"2018-07-03T15:14:04","guid":{"rendered":"http:\/\/inmunologia.webs.uvigo.es\/?p=1460"},"modified":"2018-09-17T11:47:36","modified_gmt":"2018-09-17T10:47:36","slug":"can-a-nanovaccine-be-the-solution-to-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/inmunologia.webs9.uvigo.es\/?p=1460","title":{"rendered":"Can a nanovaccine be the solution to pancreatic cancer?"},"content":{"rendered":"<div id=\"gt-src-c\" class=\"g-unit\">\n<div id=\"gt-src-p\">\n<div id=\"gt-src-wrap\" class=\"\">\n<div id=\"gt-src-cc\">\n<div>The most lethal cancer and with the worse prognosis in advanced stages is the pancreatic cancer. Therapies that are giving good results in other tumors (such as monoclonal antibodies anti-CTLA-4) are not effective in this type of cancer.<\/div>\n<\/div>\n<div><\/div>\n<div><span class=\"\">Nanovaccines are composed by small substances (nano), that could carry, either inside, or on their surface, elements called antigens.\u00a0<\/span><\/div>\n<div id=\"gt-src-cc\">\n<div><\/div>\n<div id=\"gt-src-cc-ctr\" class=\"cc-ctr gt-src-cc-normal\"><span class=\"\">In the <a href=\"http:\/\/inmunologia.webs.uvigo.es\/portfolio\/immunotherapy-in-pancreatic-cancer\/\" target=\"_blank\" rel=\"noopener\">MINECO project<\/a> lead by <a href=\"http:\/\/inmunologia.webs.uvigo.es\/members\/africa-gonzalez-fernandez\/\" target=\"_blank\" rel=\"noopener\">Prof. \u00c1frica Gonz\u00e1lez<\/a>, the researchers will use nanoparticles loaded with antigens from tumor cells to induce the immune response against pancreatic cancer cells.\u00a0<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n<p>Know more in:<\/p>\n<p><a href=\"https:\/\/www.uvigo.gal\/universidade\/comunicacion\/duvi\/pode-nanovacina-ser-solucion-fronte-cancro-pancreas\" target=\"_blank\" rel=\"noopener\">DUVI UVigo<\/a><\/p>\n<p><a href=\"https:\/\/www.gciencia.com\/saude\/inmunoterapia-cancro-letal\/\" target=\"_blank\" rel=\"noopener\">GCiencia<\/a><\/p>\n<p><a href=\"http:\/\/www.crtvg.es\/tvg\/a-carta\/telexornal-seran-3827553\" target=\"_blank\" rel=\"noopener\">CRTVG_Telexornal Ser\u00e1n_05\/07\/2018_01:02:38h<\/a><\/p>\n<p><a href=\"http:\/\/www.crtvg.es\/informativos\/investigadores-da-universidade-de-vigo-traballan-nunha-vacina-contra-o-cancro-de-pancreas\" target=\"_blank\" rel=\"noopener\">CRTVG_A Revista_08\/09\/2018<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The most lethal cancer and with the worse prognosis in advanced stages is the pancreatic cancer. Therapies that are giving <span class=\"readmore\"><a href=\"https:\/\/inmunologia.webs9.uvigo.es\/?p=1460\">Continue Reading<\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":1461,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[3],"tags":[64,66,52,67],"class_list":["post-1460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-cancer","tag-immunotherapy","tag-nanomedicine","tag-vaccines"],"jetpack_featured_media_url":"https:\/\/inmunologia.webs9.uvigo.es\/wp-content\/uploads\/2018\/07\/Proyecto-p\u00e1ncreas.jpg","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts\/1460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1460"}],"version-history":[{"count":9,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts\/1460\/revisions"}],"predecessor-version":[{"id":1481,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/posts\/1460\/revisions\/1481"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=\/wp\/v2\/media\/1461"}],"wp:attachment":[{"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmunologia.webs9.uvigo.es\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}